This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lindqvist, M. Articles by Hjemdahl, P. Search for Related Content PubMed PubMed Citation Articles by Lindqvist, M. Articles by Hjemdahl, P.

Hypertension, Vol 24, 287-296, Copyright © 1994 by American Heart Association

ARTICLES

Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension

M Lindqvist, T Kahan, A Melcher and P Hjemdahl
Department of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden.

Eleven men with mild to moderate primary hypertension were studied at rest and during mental stress before and during intravenous infusion of the calcium antagonist felodipine. Eight of them were restudied during long-term treatment (extended-release felodipine, 10 mg daily). For comparison, 10 normotensive control subjects were studied with the short-term protocol. Heart rate, cardiac output, central cardiovascular pressures, and forearm blood flow were registered. Arterial and venous sampling was performed. Norepinephrine spillovers to arterial plasma and from the forearm were assessed with the use of radiotracer methodology. In the hypertensive patients, felodipine lowered mean arterial blood pressure acutely by 8% (P < .01). Systemic vascular resistance decreased by 22% (P < .001), cardiac output increased by 20% (P < .01), and norepinephrine spillover to arterial plasma increased by 61% (P < .001). Forearm vascular resistance fell by 30% (P < .001), but norepinephrine overflow from the forearm increased by 115% (P < .001). These forearm responses were not seen in normotensive subjects despite similar systemic responses to felodipine infusion. After 8 weeks of treatment, mean arterial pressure decreased to 15% below baseline (P < .001), cardiac output returned toward pretreatment levels, and systemic vascular resistance remained low. Forearm blood flow returned toward basal levels, but forearm vascular resistance remained lowered. Total body and forearm norepinephrine spillover values were as elevated as in the acute situation. The hemodynamic "defense reaction" and the sympathoadrenal response to mental stress were essentially unaffected by felodipine. Stress-induced small elevations of neuropeptide Y-like immunoreactivity persisted during felodipine. Thus, the vasodilatation induced by felodipine elicits sympathetic counterregulation, which persists in the long term with respect to peripheral and total sympathetic activities, despite resetting of the baroreflex control of heart rate.

This article has been cited by other articles:

				G. Grassi, G. Seravalle, C. Turri, G. Bolla, and G. Mancia Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension Hypertension, March 1, 2003; 41(3): 558 - 562. [Abstract] [Full Text] [PDF]

				S. F. Fernandez, M.-H. Huang, B. A. Davidson, P. R. Knight III, and J. L. Izzo Jr Modulation of Angiotensin II Responses in Sympathetic Neurons by Cytosolic Calcium Hypertension, January 1, 2003; 41(1): 56 - 63. [Abstract] [Full Text] [PDF]

				M. Johansson, M. Elam, B. Rundqvist, G. Eisenhofer, H. Herlitz, G. Lambert, and P. Friberg Increased Sympathetic Nerve Activity in Renovascular Hypertension Circulation, May 18, 1999; 99(19): 2537 - 2542. [Abstract] [Full Text] [PDF]

				K. Sakata, M. Shirotani, H. Yoshida, and C. Kurata Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension J. Am. Coll. Cardiol., August 1, 1998; 32(2): 438 - 443. [Abstract] [Full Text] [PDF]

				B. M. Psaty, N. L. Smith, D. S. Siscovick, T. D. Koepsell, N. S. Weiss, S. R. Heckbert, R. N. Lemaitre, E. H. Wagner, and C. D. Furberg Health Outcomes Associated With Antihypertensive Therapies Used as First-Line Agents: A Systematic Review and Meta-analysis JAMA, March 5, 1997; 277(9): 739 - 745. [Abstract] [PDF]